Mallinckrodt plc Reschedules Release of Fourth Quarter and Fiscal Year 2024 Financial Results to Thursday, March 13, 2025

Rhea-AI Summary

Mallinckrodt plc (MNK), a global specialty pharmaceutical company, has rescheduled its fourth quarter and fiscal year 2024 financial results release to Thursday, March 13, 2025, before market open. The earnings conference call for investors will begin at 8:00 a.m. ET.

The company operates through two main segments: Specialty Brands, focusing on autoimmune and rare diseases in areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology, along with neonatal respiratory critical care therapies and gastrointestinal products; and Specialty Generics, which includes specialty generic drugs and active pharmaceutical ingredients.

DUBLIN, March 10, 2025 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced that it has rescheduled the release of its fourth quarter and fiscal year 2024 financial results and earnings conference call. The Company will now report earnings before market open on Thursday, March 13, 2025.

The conference call for investors will begin at 8:00 a.m. ET and can be accessed as follows:

• Live Call Participant Registration (including dial-in):  https://register.vevent.com/register/BIf17087938ddc47079bf48d6d5e7c5687

• Audio-Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/igfp4swa

• On the Investor Relations page of the Mallinckrodt website: https://ir.mallinckrodt.com/

ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

Investor Relations Contact

Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2025.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-reschedules-release-of-fourth-quarter-and-fiscal-year-2024-financial-results-to-thursday-march-13-2025-302397490.html

SOURCE Mallinckrodt plc

FAQ

When will Mallinckrodt (MNK) release its Q4 and FY 2024 earnings?

Mallinckrodt will release its Q4 and FY 2024 earnings before market open on Thursday, March 13, 2025.

What time is Mallinckrodt's (MNK) Q4 2024 earnings conference call?

The earnings conference call is scheduled for 8:00 a.m. ET on March 13, 2025.

What are the main business segments of Mallinckrodt (MNK)?

Mallinckrodt operates through Specialty Brands (rare diseases and critical care therapies) and Specialty Generics (generic drugs and active pharmaceutical ingredients).

What therapeutic areas does Mallinckrodt's (MNK) Specialty Brands segment focus on?

The Specialty Brands segment focuses on autoimmune and rare diseases in neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, neonatal respiratory care, and gastrointestinal products.